ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program
CompanyDeals

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Zhejiang Garden Biopharmaceutical Co., Ltd. (SHE: 300401) announced that it has signed the "25‑Hydroxycholesterol New Drug R&D Project Cooperation Agreement" with Guangzhou National Laboratory — establishing a joint venture to…

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Huadong Medicine’s ROR1-Targeting ADC HDM2005 Cleared for Clinical Trials by China’s NMPA

CompanyDrug

Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study

CompanyDrug

Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC

CompanyDeals

Medilink Therapeutics Partners with BioNTech to Develop ADC Products Using TMALIN Technology

CompanyDrug

Jiangsu Hengrui’s SHR-A1921 Anticipated to Gain NMPA Breakthrough Designation for Ovarian Cancer

CompanyDrug

Chinese Pharma Companies Set to Showcase Cancer Treatments at ASCO 2024

CompanyDrug

RemeGen’s Disitamab Vedotin on Track for Breakthrough Designation in Muscle Invasive Bladder Cancer

Company

AstraZeneca Sets Sights on $80 Billion Revenue Target and 20 New Molecular Entities by 2030

Show More